List of Excipients in Branded Drug VIGABATRIN FOR ORAL SOLUTION USP, 500 MG

« Back to Dashboard

Generic Drugs Containing VIGABATRIN FOR ORAL SOLUTION USP, 500 MG

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	vigabatrin	0054-0702	POVIDONE
Granules Pharmaceuticals Inc	vigabatrin	70010-083	POVIDONE

What are the Most Frequently-Used Excipients in VIGABATRIN FOR ORAL SOLUTION USP, 500 MG?

# Of NDCs	Excipient
2	POVIDONE

Vigabatrin for Oral Solution USP 500 mg: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: October 4, 2026

Vigabatrin for oral solution USP 500 mg is a niche pediatric and epilepsy product supplied as a unit-dose powder that is reconstituted in water. Its commercial value is driven less by conventional excipient differentiation than by reliable dosing, pediatric acceptability, packaging, supply continuity, and compliance with the product’s vision-loss risk controls. The active ingredient is an old small molecule with no biosimilar pathway and limited remaining composition-of-matter exclusivity.

The strongest commercial strategies are:

1. Maintain a simple, low-risk excipient system that supports rapid dissolution and Q1/Q2 regulatory defensibility.
2. Improve administration through oral-syringe compatibility, unit-dose packaging, and caregiver instructions.
3. Develop formulation or device patents around reconstitution, moisture protection, dose accuracy, and pediatric use rather than attempting to create broad active-ingredient claims.
4. Target supply reliability and lower total treatment cost in infantile spasms and refractory complex partial seizures.

What is vigabatrin for oral solution USP 500 mg?

Vigabatrin for oral solution USP 500 mg is a powder intended for dispersion or dissolution in water before oral administration. The product is used primarily for:

• Infantile spasms in patients 1 month to 2 years of age.
• Refractory complex partial seizures in adults who have responded inadequately to several alternative treatments.

The reference product is Sabril, marketed by Lundbeck in the United States. The FDA approved Sabril in 2009. The product carries a boxed warning for permanent vision loss and is distributed through a restricted risk-management program or equivalent FDA-mandated controls described in current labeling.[1]

A typical administration instruction is to dissolve one 500 mg packet in 10 mL of water, producing a nominal concentration of 50 mg/mL. The prepared solution is administered with an oral syringe. The label directs users to discard unused solution after administration rather than store it for later use.[1]

What are the key product attributes?

Attribute	Commercial and technical relevance
Dosage form	Powder for oral solution
Strength	500 mg per packet
Typical reconstituted concentration	50 mg/mL
Primary pediatric use	Infantile spasms
Adult use	Refractory complex partial seizures
Administration	Oral syringe after reconstitution
Active ingredient	Vigabatrin
Regulatory category	Small-molecule prescription drug
Primary safety issue	Permanent visual-field loss
Main formulation challenge	Dose accuracy and caregiver execution rather than long-term solution stability

What excipients are used in vigabatrin oral solution products?

The reference and generic products are designed around a minimal excipient profile. Public labeling for vigabatrin powder products identifies povidone as an inactive ingredient in the formulation.[1,2] The product is not marketed as a flavored liquid and does not require a conventional aqueous preservative system because the commercial dosage form is a dry powder reconstituted immediately before use.

Why is povidone strategically important?

Povidone can support powder processing, particle binding, wetting, and dissolution. In a unit-dose powder, it can help produce a uniform blend without introducing the regulatory and pediatric safety burden associated with multiple flavoring, sweetening, buffering, or preservative agents.

Its strategic value is limited by several factors:

• Povidone is a common pharmaceutical excipient with substantial prior-art exposure.
• Broad claims directed only to povidone-containing vigabatrin compositions would face an elevated obviousness risk.
• Higher povidone levels can affect powder flow, moisture uptake, dissolution behavior, and oral sensory characteristics.
• Pediatric use increases scrutiny of unnecessary excipients.

An excipient program should therefore focus on quantitative ranges, powder performance, reconstitution time, moisture control, and dose uniformity rather than the mere presence of povidone.

Which excipient properties matter most?

Excipient attribute	Relevance to vigabatrin 500 mg powder
Low moisture content	Reduces hydrolytic and physical instability risk
Low hygroscopicity	Supports powder flow and packet shelf life
Rapid wetting	Reduces caregiver reconstitution time
Low viscosity after reconstitution	Improves oral-syringe dosing
Low taste contribution	Important for infants and young children
Pediatric precedent	Reduces regulatory and clinical risk
Compatibility with dry blending	Supports scalable manufacturing
Low extractables and leachables burden	Important for packet and dosing-device systems

What formulation patents could protect vigabatrin oral solution products?

The most defensible formulation patent opportunities are narrow and performance-based. Vigabatrin’s age and the established powder-for-solution presentation reduce the likelihood that a broad composition patent would provide meaningful protection.

High-value claim areas

Potential claim categories include:

1. Moisture-protective unit-dose packaging
   Claims could cover a foil laminate, desiccant configuration, water-vapor transmission specification, or packet headspace designed to preserve vigabatrin powder quality.

2. Rapid-reconstitution systems
   Claims could cover a powder particle-size distribution, excipient ratio, granulation method, or mixing sequence that produces a defined concentration within a specified time.

3. Dose-volume optimization
   A formulation that provides a clinically useful concentration with a smaller administration volume could be commercially relevant in infants, provided it remains acceptable for FDA approval and accurate syringe dosing.

4. Taste-masking systems
   Taste masking may be valuable if it improves adherence without materially increasing excipient exposure or interfering with dissolution.

5. Administration kits
   A kit combining the packet, calibrated oral syringe, mixing vessel, and instructions may support device or combination-product claims, although the scope would depend on the specific architecture.

6. Manufacturing controls
   Claims directed to blend uniformity, segregation control, moisture limits, and filling accuracy can provide manufacturing know-how even when patent exclusivity is narrow.

What formulation approaches are commercially weaker?

Several approaches carry limited strategic value:

• Adding a conventional sweetener without evidence of improved pediatric adherence.
• Using a standard flavor system that creates new impurity, stability, or excipient-safety issues.
• Claiming a broad range of common binders or fillers without a demonstrated technical effect.
• Converting the product into a ready-to-use liquid without addressing preservative exposure, shelf life, packaging, and transport cost.
• Pursuing a high-concentration formulation that increases dosing risk or worsens palatability.

When does vigabatrin lose exclusivity?

The primary US regulatory exclusivity period has expired. FDA approved Sabril in 2009, and orphan-drug exclusivity generally lasts seven years from approval for the protected indication. That period therefore expired no later than 2016 for the original approvals, subject to the specific indication and regulatory history.[1,3]

Vigabatrin exclusivity timeline

Event	Approximate date	Commercial effect
Sabril approval for adult refractory complex partial seizures	2009	US market entry
Sabril approval for infantile spasms	2009	Pediatric orphan market established
Seven-year orphan exclusivity period	2009-2016	Restricted approval of the same drug for the same indication
Generic development and approval activity	From 2019	Competition expanded
Current market	Post-exclusivity	Competition based on price, supply, formulation execution, and access

Vigabatrin is a small molecule, so biosimilar rules do not apply. Competitive products proceed through the ANDA pathway as generic drugs, not through a 351(k) biosimilar application.

What is the Orange Book status of vigabatrin?

Sabril is listed in the FDA Orange Book as a reference-listed drug. The Orange Book is the central source for approved product information, therapeutic-equivalence codes, and any listed patent or exclusivity information.[3]

The practical Orange Book position is favorable to generic competition because:

• The original orphan exclusivity period has expired.
• Vigabatrin is an established small molecule.
• The dosage form is suitable for ANDA development.
• The principal commercial barriers are clinical-risk controls, manufacturing consistency, and limited market size rather than active-ingredient patent protection.

A current product-by-product Orange Book review remains necessary before filing or acquisition decisions because listed patents, delisting events, and therapeutic-equivalence information can change.

Which companies are challenging or competing with Sabril?

Generic competition has emerged in the United States, including FDA-approved vigabatrin powder-for-solution products. Dr. Reddy’s Laboratories received FDA approval for a generic vigabatrin powder for oral solution product in 2019.[4] Other market participants may enter or exit depending on supply economics, contracting, and regulatory status.

The competitive landscape includes:

Competitor type	Strategic position
Sabril	Branded reference product with established prescriber recognition
Generic vigabatrin powder	Price competition and payer substitution
Specialty distributors	Access, enrollment, and restricted-dispensing execution
Compounding pharmacies	Potential local substitution, but not a direct equivalent to an FDA-approved product
Alternative antiepileptic therapies	Clinical substitutes, particularly in infantile spasms

The relevant competitive threat is not limited to an identical packet product. ACTH, corticosteroids, ketogenic therapy, and other antiepileptic treatments can compete clinically in infantile spasms. Clinical guidelines and physician preference can therefore affect market share more than formulation differentiation alone.

What FDA regulatory barriers affect commercial launch?

The primary FDA risks are product quality, bioequivalence, pediatric administration, and restricted-use compliance.

ANDA considerations

An ANDA sponsor must demonstrate pharmaceutical equivalence and bioequivalence to the reference product. For an oral powder product, important quality attributes include:

• Assay and content uniformity.
• Particle-size distribution.
• Water content.
• Powder flow and packet fill accuracy.
• Reconstitution time.
• Appearance and redispersibility.
• Stability through the labeled shelf life.
• Compatibility with the dosing syringe.
• Consistency of the delivered dose after reconstitution.

A materially different excipient system may trigger additional FDA questions, particularly in a product used in infants. The lowest-risk strategy is generally to match the reference product’s inactive ingredients qualitatively and quantitatively where possible, then pursue differentiation through packaging, device integration, or manufacturing controls.

Risk-management requirements

Vigabatrin carries a serious vision-loss risk. The commercial product must support prescriber, patient, pharmacy, and monitoring requirements established by FDA labeling and any applicable REMS or risk-management framework.[1,5]

A formulation or packaging change that makes administration easier must not weaken:

• Dose documentation.
• Patient enrollment or dispensing controls.
• Ophthalmic monitoring instructions.
• Caregiver labeling.
• Traceability of packets and dosing devices.

How strong is the patent estate for vigabatrin oral solution?

The active-ingredient patent estate is weak for new US commercial entry because vigabatrin is an older molecule and the principal regulatory exclusivity periods have expired. The stronger intellectual-property opportunities are secondary rights.

Relative strength by IP category

IP category	Relative strength	Reason
Vigabatrin composition of matter	Low	Old molecule and expired primary exclusivity
Broad oral-solution composition	Low to moderate	Significant prior art and obviousness exposure
Specific excipient ratio	Moderate if technically supported	Requires unexpected performance or stability benefit
Moisture-protective packet	Moderate	Can create practical manufacturing and shelf-life differentiation
Reconstitution method	Moderate	Stronger if tied to measurable performance
Oral-syringe or kit design	Moderate	Potential device and combination-product protection
Manufacturing process	Moderate	Useful for trade-secret and process-control strategy
Method of use	Low to moderate	Potentially limited by prior clinical use and label scope

Method-of-use claims may still have value for dosing regimens, patient subsets, or administration protocols, but enforcement risk is high where claims overlap with the approved label or established clinical practice.

What generic launch risks exist?

A generic launch would likely occur through one of three scenarios.

Scenario 1: Immediate price-led substitution

The generic matches the reference product closely and competes through lower acquisition cost. This is the most likely scenario where multiple suppliers have approval.

Scenario 2: Limited-source supply

One or two manufacturers remain active because the patient population is small and the product requires specialty distribution. In this case, supply reliability and wholesaler coverage can matter more than nominal list price.

Scenario 3: Differentiated pediatric package

A supplier combines the 500 mg packet with a calibrated syringe, clearer reconstitution instructions, and improved moisture protection. The product remains an ANDA-based generic but gains commercial value through fewer administration errors and better caregiver experience.

The main downside risk is market erosion from low volume. Vigabatrin is a specialized product with a restricted patient population, and manufacturing economics can deteriorate quickly if several suppliers compete for a limited number of prescriptions.

What commercial opportunities exist for excipient and packaging suppliers?

The strongest opportunities are adjacent to the active formulation.

Unit-dose moisture protection

Foil laminates with low water-vapor transmission can protect powder quality and support longer shelf life. A supplier with validated sealing, printing, and child-resistant packaging capabilities can compete even when the drug formulation itself is not differentiated.

Pediatric dosing systems

A calibrated oral syringe, mixing cup, or integrated reconstitution vessel can reduce administration errors. The device must deliver the labeled concentration accurately and remain compatible with the prescribed dosing volume.

Taste and adherence improvement

A low-excipient taste-masking approach could improve acceptance in infants and young children. The commercial case requires evidence that the intervention improves administration or persistence without increasing preparation complexity.

Contract manufacturing

The small market favors manufacturers that can provide:

• Low-volume powder blending.
• High-accuracy packet filling.
• Moisture-controlled packaging.
• Stability-indicating testing.
• Flexible batch sizes.
• Specialty-pharmacy distribution support.

Geographic expansion

The United States remains attractive because of the established orphan indication and generic pathway. Europe and other regulated markets offer opportunities, but formulation, labeling, pediatric-risk controls, and reimbursement requirements differ by jurisdiction. A US formulation cannot be assumed to qualify automatically in the EU or other regions.

How does vigabatrin compare with competing epilepsy products?

Product category	Main advantage	Main limitation
Vigabatrin powder for oral solution	Established role in infantile spasms; precise packet strength	Permanent vision-loss risk and administration controls
ACTH or corticosteroids	Established infantile-spasm treatment options	Systemic adverse effects and administration burden
Other antiepileptic liquids	Ready-to-use dosing and broad availability	May have different efficacy in infantile spasms
Ketogenic therapy	Non-drug treatment option for selected patients	Dietary complexity and clinical supervision
Compounded vigabatrin	Potential local access	Lack of identical FDA-approved product status and variable quality controls

Vigabatrin’s differentiation is clinical and operational. Excipient innovation can improve delivery, but it is unlikely to replace the product’s primary value proposition: use in a defined, difficult-to-treat pediatric seizure population.

Key Takeaways

• Vigabatrin for oral solution USP 500 mg is a small-molecule powder product with expired primary US exclusivity.
• The formulation is intentionally simple, with povidone identified as an inactive ingredient in public product labeling.
• The strongest commercial opportunities are in moisture protection, packet engineering, reconstitution performance, dosing devices, and manufacturing reliability.
• Broad excipient claims are vulnerable to prior art; narrow claims tied to measurable technical effects are more defensible.
• Vigabatrin is subject to serious vision-loss warnings and FDA risk-management requirements.
• Generic competition is established, but the market remains specialized and supply economics may limit the number of viable manufacturers.
• There is no biosimilar opportunity because vigabatrin is a small molecule.
• Pediatric usability, dose accuracy, and specialty distribution are more commercially important than adding conventional flavors or sweeteners.

FAQs

Is vigabatrin oral solution a biologic or biosimilar product?

No. Vigabatrin is a synthetic small molecule. Competing products are approved as generics through the ANDA pathway rather than as biosimilars.

Can a manufacturer patent a new vigabatrin flavor?

Possibly, but a flavor patent would require a specific technical or clinical benefit. A simple substitution of a conventional flavor is likely to face obviousness and enablement challenges.

What is the most valuable excipient improvement for vigabatrin packets?

A low-moisture, rapid-reconstitution system with demonstrated dose uniformity is generally more valuable than a larger excipient package. The improvement should reduce preparation errors or improve stability.

Can vigabatrin be sold as a ready-to-use liquid?

A ready-to-use liquid would require a separate formulation and stability strategy, including preservative selection, microbial control, container closure, transport stability, and pediatric acceptability. It would not be an automatic extension of the powder product.

Does an oral syringe create separate patent value?

Yes, if the syringe or kit has a distinctive structure or improves dose accuracy, reconstitution, or caregiver compliance. The strongest protection would likely combine device claims with validated administration performance.

References

1. U.S. Food and Drug Administration. (2023). Sabril (vigabatrin) prescribing information. FDA and DailyMed labeling.

2. DailyMed. (2024). Vigabatrin for oral solution, 500 mg: Prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.

4. U.S. Food and Drug Administration. (2019). FDA approves first generic versions of Sabril to treat seizures. FDA Drug Safety and Availability.

5. U.S. Food and Drug Administration. (2024). Vigabatrin risk evaluation and mitigation strategy. FDA REMS materials.